Media Releases

Launch of Products

Over the coming months, Nutri-Pharm will be launching their latest products from their pipeline of development.

​Nutri-Pharm uses technologies to invent, innovate and augment resources, products, processes and services for the open market.  Stay tuned for further updates.

For full media release - see below

Nutri-Pharm's New Chief Executive Officer

The Nutri-Pharm Board is delighted to announce the appointment of Mr Robert Andersson as its new Chief Executive Officer (CEO).  We welcome Robert on board and believe he will bring excellent skills and drive to the company.

He is tasked with driving the successful sale or licensing of several products, including the exciting Trinsicore™ technology.  In addition, he is also tasked with increasing the value and awareness of Nutri-Pharm's intangible Agile IP assets to maximize global market share.

For full media release - see below

Working with MMIC

For the past 18 months the Medicines Manufacturing Innovation Centre (MMIC), a division of Monash University has been engaged by Nutri-Pharm to assist in the development of its latest products which will soon be launched. 

MMIC is a recognised world leader in innovative research and development.

​

Everyone at Nutri-Pharm is excited by the results of the collaboration with MMIC.

 ​For full media release - see below

Trinsicore™ Product Launch

Today Nutri-Pharm launched its latest product from its pipeline of development.

Trinsicore is a microencapsulation technology developed by Nutri-Pharm in association with the Medicines Manufacturing Innovation Centre (MMIC) at Monash University.

​

Trinsicore enhances product stability, versatility and convenience.

​For full media release - see below

Trinsicore™

The launch of Trinsicore™ (Nutri-Pharm's new microencapsulation technology) last Monday has met with great interest.  It is an exciting time for Nutri-Pharm to bring this long awaited product to market, together with the ongoing development of other products in the pipeline.

​For full media release - see below

Nutri-Pharm Differentiation Strategy

Nutri-Pharm uses technologies to invent, innovate and augment resources, products, processes and services.  Some of these innovations are suited to the Patent process but many are suited to a new model of Agile Intellectual Property (Agile IP).​

For full media release - see below

Nutri-Pharm Patents and AgileIP Explained

The traditional and conventional World-view that is widely held by much of the pharmaceutical industry is one where Patents predominate.  I agree that to some extent Patents have an important role to play but are they really the only way moving forward?  With the fast-paced and fast-changing world of today, are Patents as significant as they once were?  More importantly, what is the alternative to Patents?

For full media release - see below

Anti-Microbial Resistance (AMR) - Threats and Opportunities

Nutri-Pharm’s position is that patented antibiotics are no longer as valuable as they once were.  It often takes 10 years to develop a patented antibiotic and it may cost as much as a US$1 billion in R&D.  Patents are valid for 20 years, leaving a false hope of 10 potential years to not only recover the original investment but also generate a return of investment (ROI).  This cumbersome antibiotic patent approach is potentially costing US$2 million per week for 10 years with little to no guarantee of success.  

For full media release - see below

Trinsicore™ Technology - New Capabilities in the Beauty and Personal Care Market

Trinsicore™ technology can provide new opportunities, a fresh personality and explore possibilities to a range of beauty & personal care products.  This publication will focus on two segments; cosmetics and baby powders.

In the cosmetics segment, Nutri-Pharm technologies can revolutionise the cosmetics market by creating multi-sensory products.  This can be achieved through depth and dimension of senses to the customer experience by adding novel product capabilities.

For full media release - see below

SPX9™ Project Investor Business Case

The World Health Organisation has declared Anti-Microbial Resistance (AMR) one of the biggest threats to global health and food security. AMR occurs when bacteria resist the effects of antibiotics (often because of overuse in both human and animal terms), rendering them ineffective.  It often takes 10 years to develop a single molecule patented antibiotic and it may cost as much as a US$1 billion in R&D.  Due to extensive development costs, lengthy lead times and AMR, many corporations and organisations have exited the research area of antibiotics. 

Nutri-Pharm is well suited to address the urgency of AMR with its pioneering topical SPX9™ ointment.

For full media release - see below